The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva

In light of the recent global pandemic, Molnupiravir (MPV) or EIDD-2801, developed for the treatment of patients with uncomplicated influenza, is now being trialled for the treatment of infections caused by highly pathogenic coronaviruses, including COVID-19. A sensitive LC-MS/MS method was develope...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Pharm Biomed Anal
Päätekijät: Amara, Alieu, Penchala, Sujan Dilly, Else, Laura, Hale, Colin, FitzGerald, Richard, Walker, Lauren, Lyons, Rebecca, Fletcher, Tom, Khoo, Saye
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier B.V. 2021
Aiheet:
Short Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611757/
https://ncbi.nlm.nih.gov/pubmed/34509661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2021.114356
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia